Assetmark Inc. Decreases Position in STERIS plc $STE

Assetmark Inc. decreased its stake in STERIS plc (NYSE:STE) by 21.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,591 shares of the medical equipment provider’s stock after selling 4,003 shares during the period. Assetmark Inc.’s holdings in STERIS were worth $3,610,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of STERIS in the third quarter valued at approximately $25,000. Geneos Wealth Management Inc. raised its position in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. Spurstone Advisory Services LLC purchased a new position in STERIS during the 2nd quarter worth $29,000. Cloud Capital Management LLC acquired a new position in STERIS in the third quarter valued at $29,000. Finally, TruNorth Capital Management LLC purchased a new stake in shares of STERIS in the third quarter valued at about $37,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on STE shares. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $275.20.

Insider Buying and Selling at STERIS

In other STERIS news, VP Julia Madsen sold 5,008 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the transaction, the vice president owned 10,710 shares in the company, valued at approximately $2,806,020. This represents a 31.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.07% of the stock is currently owned by corporate insiders.

STERIS Stock Performance

STERIS stock opened at $249.87 on Thursday. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The company has a market capitalization of $24.50 billion, a price-to-earnings ratio of 34.85 and a beta of 1.03. The stock has a fifty day moving average of $256.16 and a two-hundred day moving average of $250.93. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48.

STERIS (NYSE:STE) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.STERIS’s revenue was up 9.2% on a year-over-year basis. During the same period last year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s payout ratio is 35.15%.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.